Lilly, Eli, and Company

Lilly conducted Phase I and Phase II clinical studies on daptomycin in the 1980s and early 1990s for skin and soft tissue infections, bacteraemia and endocarditis.9 In a Phase I safety study to evaluate increasing the dose to 4 mg/kg every 12 hours to treat endocarditis, two of five volunteers exhibited symptoms of muscle toxicity, including elevated creatine phosphokinase (CPK). After observing muscle toxicity with this dosing regimen, Lilly discontinued clinical development of daptomycin in 1991. 

---

Biopharmaceutical Product Development, Eli Lilly and Company, Indianapolis, Indiana 4618S... 

The TSK-GEL column is a trademark of Tosoh Haas Co. Ltd and the Waters Insulin HMWP column is a trademark of Waters Corporation. The author thanks the book s editor Chi-san Wu, the assigned peer reviewer, and the Eli Lilly and Company reviwers John Towns, Ralph Riggin, and James Kelley for their assistance, time, and professional comments. 

Dr. Dawn A. Brooks Lilly Research Laboratories Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285... 

British Patent 982,252 February 3,1965 assigned to Eli Lilly and Company... 

This narrative was first presented at Don Boyd s third annual Central Indiana Computational Chemistry Christmas Luncheon (CICCCL-3) on December 18,1997. Although it is specihc for Eli Lilly and Company, the progress and problems that transpired there were probably not too different from developments at other large, forward-looking, research-based pharmaceutical companies. 

I began work at Eli Lilly and Company in March 1942 as a laboratory aide in the analytical department. At that time, there was very little sophisticated instrnmentation in the laboratory. The most complex calculations were carried ont nsing a slide rnle. After military service in World War II and an edncational leave of absence to complete my nndergraduate studies in chemistry at Indiana University, I retnrned to the Lilly analytical group in 1947. Slide rnles were still much in evidence bnt were soon augmented with mechanical calcnlators— usually Monroe or Friden models. 

We are grateful to Dr. Sean Ekins for the opportunity to participate in this book and for his painstaking editing. We thank our many colleagues over the years for what they taught us or tried to teach us. Some of the historical events reviewed here occurred during the period of our respective tenures as members of the staff at the Lilly Research Laboratories of Eli Lilly and Company. We... 

Several companies, for example, Eli Lilly and Company, have said that their research will be made public so people may view the work and come to their own judgments about the efficacy of a drug. And, of course, scientihc research is designed from the start so that results can be shared with other scientists and replicated. 

Lisa D. Spnrlock-Brouwer Eli Lilly and Company, Greenfield, IN, USA... 

The support we received from our sponsors was much appreciated and greatly contributed to the success of the 22nd conference. On behalf of ORCS, 1 specifically thank these organizations Avantium, BASF Catalysts LLC, Eli Lilly and Company, Evonik Degussa Corporation, W.R. Grace (Davison Catalysts), Parr Instrument, Air Products, Amgen, Eastman, Umicore, Bristol-Myers Squibb, DuPont, Headwaters, HEt Lummus Technology, OMG, Seton Hall University (c/c Dr. John Sowa) and Slid Chemie. 

We are grateful to Eli Lilly and Company for their support of this work. 

Edgar W. Day, Jr., Ph.D., is a native of southern Indiana. He received his B.S. in Chemistry from the University of Notre Dame in 1958 and his Ph.D. in Analytical Chemistry from Iowa State University in 1963. Dr. Day joined the Research Laboratories of Eli Lilly and Company in 1963, working in the... 

In the context of preparing benzothienyloxy phenylpropanamines as inhibitors of serotonin and norepinephrine uptake, a group from Eli Lilly and Company has developed a two-step synthesis of benzo[fo]thiophenes (Scheme 6.193) [354]. Thus, a 2-mercapto-3-phenylpropenoic acid derivative was cyclized with iodine in 1,2-dimethoxyethane at 120 °C to give 5-fluoro-4-methoxybenzothiophene-2-carboxylic acid in 67% yield. Decarboxylation under strongly basic conditions involving 1,8-di-azabicyclo[5.4.0]undec-7-ene (DBU) as base in N,N-dimethylacetamide (DMA) as... 

Fernando Marin Eli Lilly and Company Lilly Research Center Windlesham, Surrey, UK... 

---